Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 26, 2010

View Archived Issues

SkyePharma receives FDA complete response letter regarding NDA for Flutiform

FDA sets PDUFA date for Genzyme's BLA for Lumizyme

Biogen and Swedish Orphan Biovitrum initiate dosing in B-LONG trial of rFIXFc in hemophilia B

Bayer to discontinue phase II trial of recombinant liposomal factor VIII

Clinical data shows nilotinib to be an effective front-line treatment for CML

Clinical data show safety and efficacy of dasatinib as initial therapy for CML

Shionogi discloses N-type calcium channel blockers as analgesics

Dana-Farber Cancer Institute claims novel antimalarials

Novel prostacyclin and carbaprostacyclin prodrugs in early development at Gilead

Amnestix describes novel kinase inhibitors for the treatment of cognitive disorders

Merck KGaA claims tyrosine kinase inhibitors for the treatment of cancer

Spectrum meets with FDA regarding Fusilev sNDA for colorectal cancer

Proangiogenic gene therapy reduces ventricular remodeling in diabetic rats

Roche presents OX-2 receptor antagonists for the treatment of sleep disorders

KV-11 shows preclinical potential as ocular antiangiogenic therapy

Affymax completes treatment in phase III trial of Hematide for anemia in CRF

Janssen-Cilag notifies EMEA of withdrawal of Comfyde MAA for partial-onset seizures

Merck & Co. claims novel PET imaging agents for the diagnosis of AD

Osiris completes enrollment in phase II trial of Prochymal in type 1 diabetes

Prolor Biotech reports preclinical results on interferon beta-CTP for multiple sclerosis

Anadys provides progress update on phase II study of ANA-598 in hepatitis C

EMEA recommends additional measures to manage risk for PML with Tysabri therapy

CHMP recommends suspension of marketing authorization for sibutramine

Transition Therapeutics reports results from phase II trial of TT-223 in type 2 diabetes

European Commission approves Bristol-Myers' Orencia in combination with MTX for pJIA

Dr. Reddy's and Aegis sign partnership agreement on Intravail drug delivery technology

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 3, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...